This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Summary
Carbaspirin calcium is an NSAID indicated in the treatment of short term pain and fever.
- Generic Name
- Carbaspirin calcium
- DrugBank Accession Number
- DB13612
- Background
Not Available
- Type
- Small Molecule
- Groups
- Experimental, Investigational
- Structure
Structure for Carbaspirin calcium (DB13612)
- Weight
- Average: 458.436
Monoisotopic: 458.0638211 - Chemical Formula
- C19H18CaN2O9
- Synonyms
- Carbasalate calcium
- Carbasalato calcico
- Carbasalatum calcicum
- Carbaspirin calcium
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
Indication Type Indication Combined Product Details Approval Level Age Group Patient Characteristics Dose Form Symptomatic treatment of Fever caused by common cold ••• ••• •••••• Symptomatic treatment of Fever caused by flu like illness ••• ••• •••••• Symptomatic treatment of Headache ••• ••• •••••• Symptomatic treatment of Pain caused by common cold ••• ••• •••••• Symptomatic treatment of Pain caused by flu like illness ••• ••• •••••• - Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs Browse all" title="About SNP Mediated Effects/ADRs" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">
- Not Available
Interactions
- Drug Interactions Learn More" title="About Drug Interactions" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAbacavir Carbaspirin calcium may decrease the excretion rate of Abacavir which could result in a higher serum level. Abciximab The risk or severity of bleeding and hemorrhage can be increased when Carbaspirin calcium is combined with Abciximab. Acarbose Carbaspirin calcium may increase the hypoglycemic activities of Acarbose. Acebutolol Carbaspirin calcium may decrease the antihypertensive activities of Acebutolol. Aceclofenac The therapeutic efficacy of Carbaspirin calcium can be decreased when used in combination with Aceclofenac. - Food Interactions
- Not Available
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image Irocophan - Tabletten Carbaspirin calcium (250 mg) + Acetaminophen (200 mg) + Caffeine (46 mg) Tablet Oral Dr. A. & L. Schmidgall Gmb H & Co Kg 1985-12-02 Not applicable Austria 
Iromin Vitamin C Kapseln Carbaspirin calcium (250 mg) + Ascorbic acid (100 mg) Capsule Oral Dr. A. & L. Schmidgall Gmb H & Co Kg 2009-04-15 Not applicable Austria
Categories
- ATC Codes
- N02BA15 — Carbasalate calcium
- N02BA — Salicylic acid and derivatives
- N02B — OTHER ANALGESICS AND ANTIPYRETICS
- N02 — ANALGESICS
- N — NERVOUS SYSTEM
- Drug Categories
- Agents causing hyperkalemia
- Agents that produce hypertension
- Amides
- Analgesics
- Analgesics, Non-Narcotic
- Anti-Inflammatory Agents
- Anti-Inflammatory Agents, Non-Steroidal
- Antirheumatic Agents
- Benzene Derivatives
- Blood and Blood Forming Organs
- Hydroxybenzoates
- Nephrotoxic agents
- Nervous System
- Non COX-2 selective NSAIDS
- Peripheral Nervous System Agents
- Phenols
- Platelet Aggregation Inhibitors Excl. Heparin
- Salicylates
- Salicylic Acid and Derivatives
- Sensory System Agents
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as acylsalicylic acids. These are o-acylated derivatives of salicylic acid.
- Kingdom
- Organic compounds
- Super Class
- Benzenoids
- Class
- Benzene and substituted derivatives
- Sub Class
- Benzoic acids and derivatives
- Direct Parent
- Acylsalicylic acids
- Alternative Parents
- Phenol esters / Benzoic acids / Phenoxy compounds / Benzoyl derivatives / Dicarboxylic acids and derivatives / Ureas / Carboxylic acid salts / Carboxylic acid esters / Organic calcium salts / Carboxylic acids show 5 more
- Substituents
- Acylsalicylic acid / Aromatic homomonocyclic compound / Benzoic acid / Benzoyl / Carbonic acid derivative / Carbonyl group / Carboxylic acid / Carboxylic acid derivative / Carboxylic acid ester / Carboxylic acid salt show 13 more
- Molecular Framework
- Not Available
- External Descriptors
- Not Available
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- N667F17JP1
- CAS number
- 5749-67-7
- InChI Key
- VYMUGTALCSPLDM-UHFFFAOYSA-L
- InChI
- InChI=1S/2C9H8O4.CH4N2O.Ca/c2*1-6(10)13-8-5-3-2-4-7(8)9(11)12;2-1(3)4;/h2*2-5H,1H3,(H,11,12);(H4,2,3,4);/q;;;+2/p-2
- IUPAC Name
- calcium urea bis(2-(acetyloxy)benzoate)
- SMILES
- [Ca++].NC(N)=O.CC(=O)OC1=CC=CC=C1C([O-])=O.CC(=O)OC1=CC=CC=C1C([O-])=O
References
- General References
- BASG: Iromin (Carbaspirin Calcium) Oral Tablet [Link]
- External Links
- ChemSpider
- 20651
- ChEMBL
- CHEMBL3833325
- Wikipedia
- Carbasalate_calcium
Clinical Trials
- Clinical Trials Learn More" title="About Clinical Trials" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">
Phase Status Purpose Conditions Count 4 Completed Treatment Cardiovascular Disease (CVD) / Hypertension 1 2 Completed Treatment Atrial Fibrillation / Cerebral Hemorrhage 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Powder Tablet Oral Tablet Oral 500 mg Capsule Oral - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.00848 mg/mL ALOGPS logP 3.17 ALOGPS logP 1.24 Chemaxon logS -4.7 ALOGPS pKa (Strongest Acidic) 3.41 Chemaxon pKa (Strongest Basic) -7.1 Chemaxon Physiological Charge -1 Chemaxon Hydrogen Acceptor Count 3 Chemaxon Hydrogen Donor Count 0 Chemaxon Polar Surface Area 66.43 Å2 Chemaxon Rotatable Bond Count 6 Chemaxon Refractivity 55.28 m3·mol-1 Chemaxon Polarizability 16.51 Å3 Chemaxon Number of Rings 2 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter Yes Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Not Available
- Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 186.57314 predictedDeepCCS 1.0 (2019) [M+H]+ 188.93115 predictedDeepCCS 1.0 (2019) [M+Na]+ 195.39137 predictedDeepCCS 1.0 (2019)
Drug created at June 23, 2017 20:45 / Updated at May 29, 2021 18:11